- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04787042
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
A First-In-Human Phase 1/2 Open-Label Study of Intravenous ST-067, Subcutaneous ST-067 With or Without Obinutuzumab Pre-Treatment, and ST-067 in Combination With Pembrolizumab in Subjects With Advanced Solid Malignancies
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Phase 1a is designed to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of ST067, administered by subcutaneous (SC) or intravenous (IV) dosing, in subjects with relapsed or refractory solid tumors, as well as to determine the MTD and recommended Phase 2 dose of ST067, administered SC with obinutuzumab (Gazyva®) as pretreatment in subjects with relapsed or refractory solid tumors using a modified toxicity probability interval (mTPI) design. There will be evaluations of ST-067 PK and PD effects.
Phase 2 will evaluate the preliminary efficacy of ST-067 administered at the RP2D to patients with the following tumor types. A Simon 2 stage design is used to calculate the sample size and early stopping rules will be employed in the event of lack of efficacy in any of the cohorts. RECIST 1.1 will be used to assess tumor response every 8-12 weeks.
- Melanoma (n=28)
- Renal cell carcinoma (n=25)
- Triple-negative best cancer (n=25)
- Non-small cell lung cancer (n=25)
- squamous cell carcinoma of the head and neck (n=28)
- MSI-Hi tumors (n=25)
A Simon 2 stage design is used to calculate the sample size and early stopping rules will be employed in the event of lack of efficacy in any of the cohorts. RECIST 1.1 will be used to assess tumor response every 8-12 weeks.
Safety will be assessed for each patient throughout the study.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Beatrice McQueen, Ph.D.
- Phone Number: 805-300-3912
- Email: beatrice@simchatherapeutics.com
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85258
- Recruiting
- HonorHealth Research Institute
-
Contact:
- Justin Moser, MD
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Recruiting
- Sarah Cannon Research Institute at HealthONE
-
Contact:
- Gerald Falchook, MD, MS
-
-
Connecticut
-
New Haven, Connecticut, United States, 06519
- Recruiting
- Yale Cancer Center
-
Contact:
- Harriet Kluger, MD
-
-
Florida
-
Tampa, Florida, United States, 33612
- Recruiting
- Moffitt Cancer Center
-
Contact:
- Ahmad Tarhini, MD
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Massachusetts General Hospital
-
Contact:
- Ryan Sullivan, MD
-
-
New York
-
Buffalo, New York, United States, 14263
- Recruiting
- Roswell Park Cancer Institute
-
Contact:
- Igor Puzanov, MD
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Recruiting
- Providence Cancer Institute Franz Clinic
-
Contact:
- Matthew Taylor, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 1. Male and female patients aged ≥18 years
- Must provide written informed consent and any authorizations required by local law
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Have histologically or cytologically confirmed diagnosis of advanced/metastatic solid tumor
For Phase 1a, the following solid tumors are allowed: Melanoma, Merkel cell, RCC, urothelial, NSCLC,TNBC, SCCHN, microsatellite instability high, high tumor mutation burden (Hi TMB) or mismatch repair deficient, gastric, cervical, endometrial, cutaneous squamous, small cell lung, esophageal, hepatocellular carcinoma and platinum resistant ovarian cancer.
- For patients who have developed disease progression through standard therapy, or
For patients whom standard of care therapy that prolongs survival is unavailable or unsuitable (according to the investigator and after consultation with the Medical Monitor) For Phase 1 combination therapy dose escalation, the following solid tumors are allowed: Melanoma, Merkel cell, RCC, urothelial, NSCLC (with no EGFR, TRK receptor, or ALK positive mutations/fusions), TNBC, SCCHN, MSI-Hi tumors, Hi TMB or mismatch repair deficient, gastric, cervical, endometrial, cutaneous squamous, small cell lung, esophageal, and HCC
- TNBC is diagnosed in a tumor which does not express estrogen receptor or progesterone receptor, is not human epidermal growth factor receptor 2 (HER2) 3+ on IHC or is negative by fluorescence in situ hybridization (FISH).
- MSI high tumor should have mutations in 30% or more microsatellites by PCR or be negative for MSH1/2/6 or PMS-2 by IHC.
- Hi-TMB high tumor has 10 mut/Mb or greater calculated from whole genome sequencing or whole exome sequencing
For Phase 2, the following solid tumors are allowed:
Melanoma, RCC, TNBC, NSCLC, SCCHN, and MSI-Hi tumors
- Has at least 1 measurable lesion per RECIST 1.1 criteria which has not been biopsied or received prior irradiation
- Has an accessible tumor for biopsy pre- and on-treatment (mandatory).
Exclusion Criteria:
- History of another malignancy
- Known symptomatic brain metastases requiring >10 mg/day of prednisolone or equivalent
- Significant cardiovascular disease (MI, thrombotic events,) within 6 months prior to study treatmentSignificant ECG abnormalities (Phase 1a and 2 monotherapy only) including unstable cardiac arrhythmia requiring medication, second-degree atrioventricular block type II, third degree AV
- Any degree of respiratory compromise (from either malignant or non-malignant disease)
- Evidence of an ongoing systemic bacterial, fungal, or viral infection
- Has received a live vaccine within 30 days
- Major surgery within 4 weeks
- Prior solid organ or bone marrow progenitor cell transplantation
- Prior high dose chemotherapy requiring stem cell rescue
- History of active autoimmune disorders
- Ongoing immunosuppressive therapy, including systemic or enteric corticosteroids.
- Treatment with an approved, systemic anticancer therapy or an investigational agent within 4 weeks of Day 1
- A positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral test within 28 days prior to dosing, unless there is Investigator-confirmed clinical recovery on or before C1D1
- Subjects with adrenal insufficiency
Subjects with any chemistry or hematology laboratory values that are ≥Grade 2
Additional exclusion criteria for Phase 1 combination therapy only:
- Presence of known active CNS metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging, clinically stable, and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.
- Prior radiotherapy within 2 weeks of start of study treatment or history of radiation pneumonitis.
- Presence of an active documented autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine or insulin) is not considered a form of systemic treatment and is allowed. Subjects may use topical and/or inhaled corticosteroids. However, subjects with adrenal insufficiency on replacement doses of steroids are not allowed.
- Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX40, CD137), and was discontinued from that treatment due to a Grade 3 or higher irAE
- Severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients. Subjects who have been retreated after such a reaction may be allowed after discussion with the Simcha Medical Monitor
- History of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
- NSCLC subjects that have received radiation therapy to the lung that is >30Gy within 6 months of the first dose of study treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase 2, Expansion
Phase 2 will enroll patients aged 18 years or older diagnosed with the following solid tumors: melanoma, renal cell carcinoma (RCC), triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), and microsatellite instability-high (MSI-Hi) tumors at the RP2D.
|
ST-067 is an engineered variant of human interleukin-18.
|
Experimental: Phase 1a, Dose Escalation
In the Phase 1a monotherapy study, the starting dose of ST-067 will be 30 μg/kg, with a total of 7 dose level cohorts planned. The starting dose for the IV infusion monotherapy dosing will be 60 µg/kg. Patients will be treated every week with ST-067 in all cohorts. The DLT period is 28 days after the initial dose of ST-067. According to the mTPI schema initially there will be 3 patients per cohort until the first DLT is observed at which point cohorts will be expanded according to the predetermined mTPI design. Up to 12 patients will be treated at the RP2D. |
ST-067 is an engineered variant of human interleukin-18.
|
Experimental: Phase 1a, Dose Escalation, ST-067 SC + Obinutuzumab Pre-treatment
Patients will be treated every week with ST-067 in all cohorts. The DLT period is 28 days after the initial dose of ST-067. According to the mTPI schema initially there will be 3 patients per cohort until the first DLT is observed at which point cohorts will be expanded according to the predetermined mTPI design. The starting dose for ST-067 with obinutuzumab pre-treatment will be 120µg/kg. Obinutuzumab will be administered at 1000 mg daily via IV infusion on 2 consecutive days, with the first dose given at least 7 days prior to first dose of SC ST-067. |
ST-067 is an engineered variant of human interleukin-18.
Obinutuzumab is a humanized anti-CD20 monoclonal antibody of the IgG1 subclass.
It recognizes a specific epitope of the CD20 molecule found on B-cells.
Other Names:
|
Experimental: Phase 1 combination therapy
Phase 1 dose escalation in combination with pembrolizumab will start at a dose of 30 µg/kg of ST-067 and 200 mg every 3 weeks of pembrolizumab.
Patients will be treated every week with ST-067 and every three weeks with pembrolizumab.
The MTD will be determined based on the mTPI design.
|
ST-067 is an engineered variant of human interleukin-18.
Pembrolizumab is a potent humanized immunoglobulin G4 monoclonal antibody.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Initial assessment of efficacy in phase 2
Time Frame: At 8 weeks
|
Investigator-assessed ORR, defined as either a complete response (CR) or partial response (PR) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 based on computed tomography (CT) or magnetic resonance imaging (MRI) scans
|
At 8 weeks
|
Number of Participants With Treatment-Related Adverse Events
Time Frame: Day 29
|
AE assessed by CTCAE 5.0
|
Day 29
|
Determine the maximum tolerated dose of ST-067 in phase 1a monotherapy
Time Frame: Day 29
|
Patients will be enrolled at a dose level that is predicted to be the MTD
|
Day 29
|
Evaluate the overall safety and tolerability of ST-067 in combination with pembrolizumab
Time Frame: Day 29
|
In patients experiencing insufficient response to a checkpoint inhibitor (PD-1) therapy administered alone or in combination.
|
Day 29
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PK
Time Frame: Day 29
|
Peak Plasma Concentration (Cmax)
|
Day 29
|
ADA
Time Frame: Day 29
|
Incidence of ADA to ST-067
|
Day 29
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Jeremy Barton, MD, Simcha IL-18, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Breast Diseases
- Head and Neck Neoplasms
- Kidney Neoplasms
- Carcinoma, Squamous Cell
- Breast Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Carcinoma, Renal Cell
- Carcinoma
- Squamous Cell Carcinoma of Head and Neck
- Triple Negative Breast Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Pembrolizumab
- Obinutuzumab
Other Study ID Numbers
- ST-067-001
- KEYNOTE-E64 (Other Identifier: Merck)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Melanoma
-
H. Lee Moffitt Cancer Center and Research InstituteTurnstone Biologics, Corp.RecruitingMetastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous MelanomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IA Melanoma | Stage IB Melanoma | Stage IIA MelanomaUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); University of VirginiaCompletedStage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma | Stage 0 Skin Melanoma | Stage I Skin Melanoma | Stage II Skin MelanomaUnited States
-
MelanomaPRO, RussiaRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma, Stage II | Melanoma, Uveal | Melanoma in Situ | Melanoma, OcularRussian Federation
-
National Cancer Institute (NCI)CompletedStage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIB Melanoma | Stage IIC MelanomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA MelanomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Melanoma | Stage IV Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage...United States
-
Emory UniversityGenentech, Inc.Active, not recruitingStage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Unresectable Melanoma | Stage III Melanoma | Stage IIIA Skin Melanoma | Cutaneous Melanoma, Stage III | Cutaneous Melanoma, Stage IVUnited States
-
BiocadRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma Metastatic | Melanoma Unresectable | Melanoma AdvancedIndia, Russian Federation, Belarus
Clinical Trials on ST-067
-
Nanyang Technological UniversityActive, not recruitingPhysiological Outcomes of High-intensity Interval Training With Post-exercise Blood Flow RestrictionExercise PerformanceSingapore
-
Abbott Medical DevicesTerminatedCoronary Artery DiseaseUnited States
-
Istituto Superiore di Osteopatia di MilanoCompletedHealthy | Osteopathic ManipulationItaly
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)RecruitingPeripheral NeuropathyUnited States
-
University Hospitals Coventry and Warwickshire...RecruitingNervous System Diseases | Neuromuscular Diseases | Respiratory Failure | Respiratory Insufficiency | Amyotrophic Lateral Sclerosis | Sleep-Disordered Breathing | Neuro-Degenerative Disease | Neuron Disease, MotorUnited Kingdom
-
University of ThessalyRecruiting
-
SIGA TechnologiesNational Institute of Allergy and Infectious Diseases (NIAID)Completed
-
Sangamo TherapeuticsEnrolling by invitationFabry Disease | Fabry Disease, Cardiac VariantUnited States, Australia, United Kingdom
-
Thomas Jefferson UniversityJohns Hopkins University; Dartmouth-Hitchcock Medical CenterCompletedAge-Related Macular DegenerationUnited States
-
SIGA TechnologiesNational Institutes of Health (NIH)CompletedOrthopoxviral DiseaseUnited States